<DOC>
	<DOCNO>NCT00425971</DOCNO>
	<brief_summary>BMEC-1217B abbreviate version old Chinese formulation . The ratio component adopt sponsor follow observation BMEC-1217B prepare ratio result best pharmacological profile vitro bioactivities . BMEC-1217B studied pharmacological activity release cysteinyl leukotrienes , IL-4 TNF-alpha vitro airway hyperreactivity . The result indicate BMEC-1217B inhibit synthesis several key pro-inflammatory mediator involve pathophysiology allergic asthma also improve lung function mouse model allergic asthma . The purpose study evaluate safety tolerability increase dose BMEC-1217B administer orally healthy volunteer .</brief_summary>
	<brief_title>Safety Study Anti-Asthma Agent BMEC-1217B</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Nonsmoking healthy adult 20 40 year old . 2 . Determined good health base medical history , clinical laboratory test value within normal range . Body weight within 20 % ideal body weight [ ( height 80 ) x 0.7 ] . 3 . No recent history drug alcohol abuse within one year prior study enrollment 4 . Signed informed consent form . 1 . Has condition interfere ability subject comply requirement study . 2 . Has know allergy study drug . 3 . Has acute illness surgery within 28 day prior study enrollment 4 . Has participate investigational trial within 28 day prior study enrollment . 5 . Has take prescription medication and/or overthecounter medication*4 and/or botanical medication within 28 day prior study enrollment . 6 . Has alcohol caffeine consumption within 24 hour prior administration study drug . 7 . Has evidence significant renal , cardiovascular , hepatic , hematopoetic , neurological , pulmonary gastrointestinal pathology , medical reason disease might interfere study objective , determine investigator . 8 . Has donation receive 450 mL blood within 28 day prior study enrollment . 9 . Female subject child bear potential pregnant , nursing , agree practice effective birth control time period 14 day administration study drug 28 day administration study drug , irregular abnormal menstruation . 10 . Clinically significant deviation normal physical examination finding , principal investigator 's judgment , may interfere study evaluation affect subject safety . 11 . Test positive HIV , HBV HCV 12 . Test result indicate liver function failure 13 . Has diagnose Diabetes Mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>